个人中心 - 老虎社区

sachisachi

IP属地：未知

帖子 · 8帖子 · 8
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- sachisachisachisachi
  ·2021-06-23
  Fair competition I guess
  Why I Believe NIO Will Beat Out Tesla
  The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.Super fans of the latest and greatest high-endTesla, Inc. model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.The go
  Why I Believe NIO Will Beat Out Tesla
  103 2
  3
  分享
  举报
- sachisachisachisachi
  ·2021-06-16
  Awesome!
  非常抱歉，此主贴已删除
  60 评论
  点赞
  分享
  举报
- sachisachisachisachi
  ·2021-06-15
  Good read
  非常抱歉，此主贴已删除
  50 评论
  点赞
  分享
  举报
- sachisachisachisachi
  ·2021-06-15
  Yes to effective vaccines!
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  It was "better late than never" for Novavax, Inc.NVAX, as the biopharma finally got around to announ
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  172 评论
  点赞
  分享
  举报
- sachisachisachisachi
  ·2021-06-11
  💎 🙌🏻
  AMC Entertainment: Embracing The Absurd
  Summary I am cautiously bullish even with AMC severely overvalued. AMC was granted two gifts so far
  AMC Entertainment: Embracing The Absurd
  155 评论
  点赞
  分享
  举报
- sachisachisachisachi
  ·2021-06-11
  Nio ftw 💪🏻
  NIO: Buy This Chinese EV Manufacturer While It's Still Cheap
  NIO is a dominant EV manufacturer in the electric SUV segment in China.Despite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla.As the Chinese EV market will continue to aggressively expand in the upcoming years, we believe that NIO has all the chances to create additional shareholder value in the future.Founded in 2014, NIO is an electric vehicle manufacturer that's headquartered in Shanghai, China. The company mostly spec
  NIO: Buy This Chinese EV Manufacturer While It's Still Cheap
  113 评论
  点赞
  分享
  举报
- sachisachisachisachi
  ·2021-06-07
  The next GameStop!
  3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will
  The long-term prospects look much brighter for these great companies.
  3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will
  453 评论
  2
  分享
  举报
- sachisachisachisachi
  ·2021-06-07
  [Doubt]
  非常抱歉，此主贴已删除
  90 评论
  3
  分享
  举报
暂无关注

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581911525047676","uuid":"3581911525047676","gmtCreate":1618817977778,"gmtModify":1623076087972,"name":"sachisachi","pinyin":"sachisachi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"80.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":121673797,"gmtCreate":1624463736319,"gmtModify":1634005720485,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Fair competition I guess","listText":"Fair competition I guess","text":"Fair competition I guess","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/121673797","repostId":"1145825451","repostType":4,"repost":{"id":"1145825451","kind":"news","pubTimestamp":1624433586,"share":"https://www.laohu8.com/m/news/1145825451?lang=&edition=full","pubTime":"2021-06-23 15:33","market":"us","language":"en","title":"Why I Believe NIO Will Beat Out Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1145825451","media":"InvestorPlace","summary":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.Super fans of the latest and greatest high-endTesla, Inc. model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.The go","content":"<blockquote>\n <b>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.</b>\n</blockquote>\n<p>Super fans of the latest and greatest high-end<b>Tesla, Inc.</b>(NASDAQ:<b>TSLA</b>) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.</p>\n<p><img src=\"https://static.tigerbbs.com/b294a3604c7ba82bd19b3c70be3a4020\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: nrqemi / Shutterstock.com</p>\n<p>Musk wrote there was… “No need, as Plaid is just so good.”</p>\n<p>The Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.</p>\n<p>Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.</p>\n<p>As a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.</p>\n<p>This “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.</p>\n<p>Both the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.</p>\n<p>Clearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”</p>\n<p>As someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know do<i>not</i>want to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.</p>\n<p>What Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.</p>\n<p>The good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.</p>\n<p>This is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.</p>\n<p>However, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.</p>\n<p><b>Taking Advantage of the EV Revolution’s Profit Potential</b></p>\n<p>I’m talking about&nbsp;<b>Nio, Inc.</b>(NYSE:<b>NIO</b>). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on my<b><i>Platinum Growth Club</i></b>Model Portfolio back in February.</p>\n<p>The company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.</p>\n<p>The company is also partnering with cutting-edge chip companies like<b>NVIDIA Corporation</b>(NASDAQ:<b>NVDA</b>), another one of my<b><i>Platinum Growth Club</i></b>Model Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.</p>\n<p>Now, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.</p>\n<p>With the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.</p>\n<p>That means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.</p>\n<p>Shares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”</p>\n<p>Interestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.</p>\n<p>In other words, NIO represents the<b>crème de la crème</b>of EV stocks right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why I Believe NIO Will Beat Out Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy I Believe NIO Will Beat Out Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 15:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ...</p>\n\n<a href=\"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145825451","content_text":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.\nSource: nrqemi / Shutterstock.com\nMusk wrote there was… “No need, as Plaid is just so good.”\nThe Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.\nInstead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.\nAs a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.\nThis “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.\nBoth the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.\nClearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”\nAs someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know donotwant to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.\nWhat Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.\nThe good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.\nThis is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.\nHowever, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.\nTaking Advantage of the EV Revolution’s Profit Potential\nI’m talking about Nio, Inc.(NYSE:NIO). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on myPlatinum Growth ClubModel Portfolio back in February.\nThe company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.\nThe company is also partnering with cutting-edge chip companies likeNVIDIA Corporation(NASDAQ:NVDA), another one of myPlatinum Growth ClubModel Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.\nNow, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.\nWith the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.\nThat means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.\nShares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”\nInterestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.\nIn other words, NIO represents thecrème de la crèmeof EV stocks right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169761044,"gmtCreate":1623851274988,"gmtModify":1634027096114,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169761044","repostId":"1175265723","repostType":4,"isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187461331,"gmtCreate":1623762201623,"gmtModify":1634028785067,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187461331","repostId":"2143735244","repostType":4,"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187487175,"gmtCreate":1623762092597,"gmtModify":1634028788793,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Yes to effective vaccines!","listText":"Yes to effective vaccines!","text":"Yes to effective vaccines!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187487175","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188107168,"gmtCreate":1623423185554,"gmtModify":1634033355869,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"💎 🙌🏻&nbsp;","listText":"💎 🙌🏻&nbsp;","text":"💎 🙌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188107168","repostId":"1189985902","repostType":4,"repost":{"id":"1189985902","kind":"news","pubTimestamp":1623416781,"share":"https://www.laohu8.com/m/news/1189985902?lang=&edition=full","pubTime":"2021-06-11 21:06","market":"us","language":"en","title":"AMC Entertainment: Embracing The Absurd","url":"https://stock-news.laohu8.com/highlight/detail?id=1189985902","media":"seekingalpha","summary":"Summary\n\nI am cautiously bullish even with AMC severely overvalued.\nAMC was granted two gifts so far","content":"<p><b>Summary</b></p>\n<ul>\n <li>I am cautiously bullish even with AMC severely overvalued.</li>\n <li>AMC was granted two gifts so far, the ending of the pandemic and millions of apes descending onto the scene.</li>\n <li>Adam Aron and the AMC team must be thinking creatively for ultimate survival.</li>\n</ul>\n<p>Deep breath and exhale - I can’t believe I am about to do this. First of all I must preface that I am of sound mind (I think) and I do recognize an extremely overvalued stock when I see it. However, there are times that an out of the box opportunity surfaces that I simply just cannot ignore regardless of current valuation. I have a tendency to focus more on looking ahead for opportunity versus past and current performance and opportunity loss.</p>\n<p>With that said, I do caution if you fit any of the following categories, please close out of this page and select something else to read:</p>\n<ul>\n <li>Only invest in proven net income generating companies with a PE ratio less than 12.</li>\n <li>Won’t touch anything that hasn’t progressively increased dividends over the last ten years.</li>\n <li>Leery of any company that is saddled with debt, overburdened by operating cost structure, struggling with generating revenue stream, ever increasing competition and a seemingly endless flow of dilutive share offerings.</li>\n</ul>\n<p><b>Reading on</b></p>\n<p>Now if you’re still reading you are either not of sound mind, have an innovative outlook that enjoys exploring creative alternatives that challenges conventional wisdom or you’re an ape. I’m sure there may be many that fit all three. Regardless of whether you fit into one, two or all three of the characteristics above, you may want to be prepared for my next statement. In fact, you may need to walk away and return later after digesting this. I won’t fault anyone that doesn’t return.</p>\n<p>I am long AMC Entertainment Holdings, Inc. (NYSE:AMC).</p>\n<p>Do not get me wrong, I wholeheartedly agree with most of the points that are made by countless analysts regarding the insanity surrounding AMC. Using basic fundamentals, an investor doesn’t need to look any further than the following data to conclude that it is best to stay away. Operating income generation is historically less than interest payments as shown below.</p>\n<p><img src=\"https://static.tigerbbs.com/92a417e57d7b2c8b0840fef390a29a48\" tg-width=\"1200\" tg-height=\"742\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: company data</i></p>\n<p>It does not take rocket science to surmise that this is a very capital intensive company in the dynamically changing world of entertainment that is saddled with debt and a fairly clear path to bankruptcy under complacent strategic focus. In fact, my article,<i>Cinemark Improves Liquidity And The Moviegoer Experience</i>, published on December 2, 2020 took a bullish stance as Cinemark (CNK) had a clear liquidity advantage as well as a front running position in providing an enhanced consumer experience. Although Cinemark still has competitive advantages over rival AMC, tables are turning rapidly.</p>\n<p><b>The magical lamp</b></p>\n<p>It should be obvious to everyone on the planet that Adam Aron, CEO of AMC must have stumbled upon the magical genie lamp, most likely buried in the boxes of movie props from Aladdin. Imagine Aron’s surprise when he realized the prop actually contained the powerful genie. With three wishes at his fingertips, the pursuit to save AMC promptly ensued.</p>\n<p><b>Wish 1: end the pandemic</b></p>\n<p>The obvious first wish, ending the pandemic to allow people to return to some normalcy may have been somewhat selfishly aimed at getting theaters filled, but in reality, we all would have made that the first wish as well. It still may take some time to get everyone back on board with enough confidence to fill the seats. If the images from the first full capacity Bruins game on Saturday May 29 are any indicator, most are ready.</p>\n<p><img src=\"https://static.tigerbbs.com/fece3e8653eec6c62a1f820a89127ac3\" tg-width=\"640\" tg-height=\"328\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Author</i></p>\n<p><b>Wish 2: liquidity</b></p>\n<p>By the humorous way the second wish was granted, it is apparent that Adam Aron stumbled upon the lamp containing the greatest genie of all time. There’s only one genie that could creatively and comically have millions of apes descend onto the movie scene chanting the ‘Save AMC’ mantra. As the 6 month market cap chart below shows, the mega big screen and comedic spirit infused genie isn’t only hilarious but effective too. The ape driven liquidity improvements are buying AMC the much needed capital for survival and future growth.</p>\n<p><img src=\"https://static.tigerbbs.com/bfe58a62e3e505e194f7696d896e6d59\" tg-width=\"640\" tg-height=\"236\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source:SA Charts</i></p>\n<p>Surely there aren’t enough words or tweets that Adam Aron can express for the gratitude he owes to the diamond handed WSB AMC apes. With a wink to the heavens, the Investor Connect program as texted by Aron is a nice gesture of gratitude and should prove to be well received by the truly diamond handed.</p>\n<p><img src=\"https://static.tigerbbs.com/15cc04b8b658fc8fd1e372b7e911c9bd\" tg-width=\"400\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Twitter</i></p>\n<p>The second wish to repair liquidity is still in the mid-grant stage and by no means over or even a foregone conclusion as many battles are ongoing across multiple fronts.</p>\n<p>First and foremost, the psychological internal battle that every investor deals with, never truly knowing when to buy or sell, is the largest risk to share price. The more a stock becomes disjointed with the fundamental realities, the greater the struggle. Investors internally debate, rationalize and self-negotiate with the following unknown questions:</p>\n<ul>\n <li>Is a double, triple or a ten bagger enough?</li>\n <li>Should I take short term profits on all or some?</li>\n <li>Momentum seems strong, should I buy more at these levels in hopes to ride it higher?</li>\n <li>Should I just keep it on the table for the long term?</li>\n <li>Who will blink first?</li>\n</ul>\n<p>These psychological effects normally follow a scripted playbook that technical analysts can normally rely on. However, meme stocks are not normal by any stretch as witnessed by the extreme emotional back and forth battle between sellers and buyers. Sellers will be hanging on for dear life as they attempt to remain solvent as they wait out the inevitable selling frenzy. Buyers will attempt to hang on for as long as possible in hopes to inflict as much pain on the sellers as possible, also keeping an eye on solvency.</p>\n<p>Objectively and mathematically speaking, bulls will always have an inherent advantage. Downward losses in any equity is finite while upward gains in any given equity is infinite. It really does come down to supply and demand. Bears rely on poor management, a failing business model and most importantly the unwillingness of bulls to fund failure.</p>\n<p>AMC was given a great gift and they have capitalized through much needed dilution. Adam Aron and the AMC team must be extremely diligent not to go all paper-handed. The delicate balancing act on the head of the pin with respect to over diluting could most certainly trigger a selloff of epic proportions. The paper-hand temptations exist everywhere and the bears know it and rely on it. That is why the fundamentals do matter a lot and must be drastically and positively changed and in a hurry.</p>\n<p>Now that millions of apes have put a band aid on AMC, it is imperative for Aron to put forth a winning strategic business plan leading into any further dilution. Dilution for debt recovery alone won't do enough. Dilution for growth and earnings is the only viable solution.</p>\n<p><b>The final wish</b></p>\n<p>So we all know what Adam Aron’s first two wishes were. One to end the pandemic and the other to band aid liquidity issues, which both were granted. Now here we are waiting to see what the third wish will be. The third wish needs to be innovative, forward thinking, large scale and most importantly deliver explosive ever-increasing profitable growth. Adam Aron better be thinking in comparative scale of what Steve Jobs brought to the table for Apple when he re-took the helm in 1997.</p>\n<p>Of course, AMC can take the windfall for what it is to restructure debt while plodding along the same narrow path of falling revenues and increasing operating costs, which will certainly buy some time. However, debt reduction and restructuring should not be investors' primary concern. Investors must be looking for AMC to use the next capital raise for fundamental change that profitably taps into the enormous entertainment market.</p>\n<p>With these gifts that have magically appeared seemingly from thin air, AMC has this one opportunity to redefine itself. AMC can take a multitude of directions to put big smiles on the apes funding this defining moment. Here are a few off-the-cuff thoughts that could be game changing as examples of where this investor's mind is as far as scale.</p>\n<p>Build upon the early successes of the private theater rental program.</p>\n<ul>\n <li>Reduce the number of large capacity screening rooms for more creatively designed rooms that can accommodate smaller gatherings.</li>\n <li>Utilize these rooms for other events beyond movies such as the big sports game, video gaming play / tournaments and special early viewings of exclusive streamed content.</li>\n <li>Add onsite or online betting for the sporting events.</li>\n</ul>\n<p>A game-changing acquisition, merger or partnerships to capture a broader market presence.</p>\n<ul>\n <li>A few more ape dollars in share price could allow for an offering to Cinemark shareholders that could easily absorb their $2.8B market cap. The combined force would help level the playing field with the vertical influences within the entertainment industry.</li>\n <li>A synergistic shared real estate partnership with WSB perennial favorite GameStop (GME) as theaters share commonality for both movie watching and video game-play.</li>\n</ul>\n<p>Although creating scenarios and narratives are fun and are a big part of my strategy when looking for coal with diamond possibilities, investor must not get buried in whimsical ideals and ignore realities. AMC leadership will determine if this meme gift will be game changing for investors or will just merely be a cash grab for executives and insiders.</p>\n<p><b>Conclusion</b></p>\n<p>My bullish stance is completely predicated on the opportunity that this 'Save AMC' effort is giving AMC. The next moves by Adam Aron and AMC will certainly be a driving force in determining whether or not my hands are made of diamonds or of paper. Reopening theaters and going back to the dismal mode of operation that existed pre-COVID alone will not suffice. In fact, if that is the plan, sellers should hang on for the round-trip in share price.</p>\n<p>Of course, like everyone, the internal struggles that force buying and selling are always present. For now, I remain cautiously optimistic, AMC led by Adam Aron will lean diamond while putting forth a big effort for the ages. The first sign of AMC weakness in strategic vision will send this shareholder to the theater's exit. The pressure is on AMC to turn their hands of coal into diamond. There's a community of apes relying on it.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Entertainment: Embracing The Absurd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Entertainment: Embracing The Absurd\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434292-amc-embracing-the-absurd><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nI am cautiously bullish even with AMC severely overvalued.\nAMC was granted two gifts so far, the ending of the pandemic and millions of apes descending onto the scene.\nAdam Aron and the AMC ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434292-amc-embracing-the-absurd\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://seekingalpha.com/article/4434292-amc-embracing-the-absurd","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1189985902","content_text":"Summary\n\nI am cautiously bullish even with AMC severely overvalued.\nAMC was granted two gifts so far, the ending of the pandemic and millions of apes descending onto the scene.\nAdam Aron and the AMC team must be thinking creatively for ultimate survival.\n\nDeep breath and exhale - I can’t believe I am about to do this. First of all I must preface that I am of sound mind (I think) and I do recognize an extremely overvalued stock when I see it. However, there are times that an out of the box opportunity surfaces that I simply just cannot ignore regardless of current valuation. I have a tendency to focus more on looking ahead for opportunity versus past and current performance and opportunity loss.\nWith that said, I do caution if you fit any of the following categories, please close out of this page and select something else to read:\n\nOnly invest in proven net income generating companies with a PE ratio less than 12.\nWon’t touch anything that hasn’t progressively increased dividends over the last ten years.\nLeery of any company that is saddled with debt, overburdened by operating cost structure, struggling with generating revenue stream, ever increasing competition and a seemingly endless flow of dilutive share offerings.\n\nReading on\nNow if you’re still reading you are either not of sound mind, have an innovative outlook that enjoys exploring creative alternatives that challenges conventional wisdom or you’re an ape. I’m sure there may be many that fit all three. Regardless of whether you fit into one, two or all three of the characteristics above, you may want to be prepared for my next statement. In fact, you may need to walk away and return later after digesting this. I won’t fault anyone that doesn’t return.\nI am long AMC Entertainment Holdings, Inc. (NYSE:AMC).\nDo not get me wrong, I wholeheartedly agree with most of the points that are made by countless analysts regarding the insanity surrounding AMC. Using basic fundamentals, an investor doesn’t need to look any further than the following data to conclude that it is best to stay away. Operating income generation is historically less than interest payments as shown below.\n\nSource: company data\nIt does not take rocket science to surmise that this is a very capital intensive company in the dynamically changing world of entertainment that is saddled with debt and a fairly clear path to bankruptcy under complacent strategic focus. In fact, my article,Cinemark Improves Liquidity And The Moviegoer Experience, published on December 2, 2020 took a bullish stance as Cinemark (CNK) had a clear liquidity advantage as well as a front running position in providing an enhanced consumer experience. Although Cinemark still has competitive advantages over rival AMC, tables are turning rapidly.\nThe magical lamp\nIt should be obvious to everyone on the planet that Adam Aron, CEO of AMC must have stumbled upon the magical genie lamp, most likely buried in the boxes of movie props from Aladdin. Imagine Aron’s surprise when he realized the prop actually contained the powerful genie. With three wishes at his fingertips, the pursuit to save AMC promptly ensued.\nWish 1: end the pandemic\nThe obvious first wish, ending the pandemic to allow people to return to some normalcy may have been somewhat selfishly aimed at getting theaters filled, but in reality, we all would have made that the first wish as well. It still may take some time to get everyone back on board with enough confidence to fill the seats. If the images from the first full capacity Bruins game on Saturday May 29 are any indicator, most are ready.\n\nSource: Author\nWish 2: liquidity\nBy the humorous way the second wish was granted, it is apparent that Adam Aron stumbled upon the lamp containing the greatest genie of all time. There’s only one genie that could creatively and comically have millions of apes descend onto the movie scene chanting the ‘Save AMC’ mantra. As the 6 month market cap chart below shows, the mega big screen and comedic spirit infused genie isn’t only hilarious but effective too. The ape driven liquidity improvements are buying AMC the much needed capital for survival and future growth.\n\nSource:SA Charts\nSurely there aren’t enough words or tweets that Adam Aron can express for the gratitude he owes to the diamond handed WSB AMC apes. With a wink to the heavens, the Investor Connect program as texted by Aron is a nice gesture of gratitude and should prove to be well received by the truly diamond handed.\n\nSource: Twitter\nThe second wish to repair liquidity is still in the mid-grant stage and by no means over or even a foregone conclusion as many battles are ongoing across multiple fronts.\nFirst and foremost, the psychological internal battle that every investor deals with, never truly knowing when to buy or sell, is the largest risk to share price. The more a stock becomes disjointed with the fundamental realities, the greater the struggle. Investors internally debate, rationalize and self-negotiate with the following unknown questions:\n\nIs a double, triple or a ten bagger enough?\nShould I take short term profits on all or some?\nMomentum seems strong, should I buy more at these levels in hopes to ride it higher?\nShould I just keep it on the table for the long term?\nWho will blink first?\n\nThese psychological effects normally follow a scripted playbook that technical analysts can normally rely on. However, meme stocks are not normal by any stretch as witnessed by the extreme emotional back and forth battle between sellers and buyers. Sellers will be hanging on for dear life as they attempt to remain solvent as they wait out the inevitable selling frenzy. Buyers will attempt to hang on for as long as possible in hopes to inflict as much pain on the sellers as possible, also keeping an eye on solvency.\nObjectively and mathematically speaking, bulls will always have an inherent advantage. Downward losses in any equity is finite while upward gains in any given equity is infinite. It really does come down to supply and demand. Bears rely on poor management, a failing business model and most importantly the unwillingness of bulls to fund failure.\nAMC was given a great gift and they have capitalized through much needed dilution. Adam Aron and the AMC team must be extremely diligent not to go all paper-handed. The delicate balancing act on the head of the pin with respect to over diluting could most certainly trigger a selloff of epic proportions. The paper-hand temptations exist everywhere and the bears know it and rely on it. That is why the fundamentals do matter a lot and must be drastically and positively changed and in a hurry.\nNow that millions of apes have put a band aid on AMC, it is imperative for Aron to put forth a winning strategic business plan leading into any further dilution. Dilution for debt recovery alone won't do enough. Dilution for growth and earnings is the only viable solution.\nThe final wish\nSo we all know what Adam Aron’s first two wishes were. One to end the pandemic and the other to band aid liquidity issues, which both were granted. Now here we are waiting to see what the third wish will be. The third wish needs to be innovative, forward thinking, large scale and most importantly deliver explosive ever-increasing profitable growth. Adam Aron better be thinking in comparative scale of what Steve Jobs brought to the table for Apple when he re-took the helm in 1997.\nOf course, AMC can take the windfall for what it is to restructure debt while plodding along the same narrow path of falling revenues and increasing operating costs, which will certainly buy some time. However, debt reduction and restructuring should not be investors' primary concern. Investors must be looking for AMC to use the next capital raise for fundamental change that profitably taps into the enormous entertainment market.\nWith these gifts that have magically appeared seemingly from thin air, AMC has this one opportunity to redefine itself. AMC can take a multitude of directions to put big smiles on the apes funding this defining moment. Here are a few off-the-cuff thoughts that could be game changing as examples of where this investor's mind is as far as scale.\nBuild upon the early successes of the private theater rental program.\n\nReduce the number of large capacity screening rooms for more creatively designed rooms that can accommodate smaller gatherings.\nUtilize these rooms for other events beyond movies such as the big sports game, video gaming play / tournaments and special early viewings of exclusive streamed content.\nAdd onsite or online betting for the sporting events.\n\nA game-changing acquisition, merger or partnerships to capture a broader market presence.\n\nA few more ape dollars in share price could allow for an offering to Cinemark shareholders that could easily absorb their $2.8B market cap. The combined force would help level the playing field with the vertical influences within the entertainment industry.\nA synergistic shared real estate partnership with WSB perennial favorite GameStop (GME) as theaters share commonality for both movie watching and video game-play.\n\nAlthough creating scenarios and narratives are fun and are a big part of my strategy when looking for coal with diamond possibilities, investor must not get buried in whimsical ideals and ignore realities. AMC leadership will determine if this meme gift will be game changing for investors or will just merely be a cash grab for executives and insiders.\nConclusion\nMy bullish stance is completely predicated on the opportunity that this 'Save AMC' effort is giving AMC. The next moves by Adam Aron and AMC will certainly be a driving force in determining whether or not my hands are made of diamonds or of paper. Reopening theaters and going back to the dismal mode of operation that existed pre-COVID alone will not suffice. In fact, if that is the plan, sellers should hang on for the round-trip in share price.\nOf course, like everyone, the internal struggles that force buying and selling are always present. For now, I remain cautiously optimistic, AMC led by Adam Aron will lean diamond while putting forth a big effort for the ages. The first sign of AMC weakness in strategic vision will send this shareholder to the theater's exit. The pressure is on AMC to turn their hands of coal into diamond. There's a community of apes relying on it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188913037,"gmtCreate":1623419165329,"gmtModify":1634033463501,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"Nio ftw 💪🏻","listText":"Nio ftw 💪🏻","text":"Nio ftw 💪🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188913037","repostId":"1146386859","repostType":4,"repost":{"id":"1146386859","kind":"news","pubTimestamp":1623417074,"share":"https://www.laohu8.com/m/news/1146386859?lang=&edition=full","pubTime":"2021-06-11 21:11","market":"us","language":"en","title":"NIO: Buy This Chinese EV Manufacturer While It's Still Cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1146386859","media":"seekingalpha","summary":"NIO is a dominant EV manufacturer in the electric SUV segment in China.Despite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla.As the Chinese EV market will continue to aggressively expand in the upcoming years, we believe that NIO has all the chances to create additional shareholder value in the future.Founded in 2014, NIO is an electric vehicle manufacturer that's headquartered in Shanghai, China. The company mostly spec","content":"<p><b>Summary</b></p>\n<ul>\n <li>NIO is a dominant EV manufacturer in the electric SUV segment in China.</li>\n <li>Despite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla.</li>\n <li>As the Chinese EV market will continue to aggressively expand in the upcoming years, we believe that NIO has all the chances to create additional shareholder value in the future.</li>\n</ul>\n<p>NIO(NYSE:NIO)is a dominant EV manufacturer in the electric SUV segment in China. It has been constantly increasing its deliveries every quarter, its revenues have been growing at a triple-digit rate in recent years, and despite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla(NASDAQ:TSLA). While NIO's stock has depreciated last month, there's every reason to believe that its growth story is far from over, as the Chinese EV market will continue to aggressively expand in the upcoming years and the penetration of electric vehicles on its roads is only going to increase. Considering this, the company has all the chances to create additional shareholder value in the long run.</p>\n<p><b>Dominating the Chinese Market</b></p>\n<p>Founded in 2014, NIO is an electric vehicle manufacturer that's headquartered in Shanghai, China. The company mostly specializes in the development of luxurious electric SUVs and just likeXPeng(XPEV), it manufactures and sells its cars online and through its showrooms across China. In addition, NIO also offers various energy-related solutions such as home charging stations, mobile charging services, and others to its customers.</p>\n<p>In recent years, the company has been aggressively growing, as the deliveries of its cars have been steadily increasing quarter after quarter, which led to the appreciation of its stock. However, due to the overall market selloff last month, NIO's stock along with stocks of other EV manufacturers such as XPeng, Tesla, and Li Auto (LI) evaporated most of its YTD gains and are currently underperforming the S&amp;P 500 Index.</p>\n<p><img src=\"https://static.tigerbbs.com/23b2ed509a529a876c423f3e9426be3f\" tg-width=\"1280\" tg-height=\"443\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Chart: Seeking Alpha</i></p>\n<p>Despite this, there's every reason to believe that NIO's stock will recover, as the company's successful performance in Q1 shows that its growth story is far from over. InQ1alone NIO beat the Street expectations by $160 million and generated $1.22 billion in revenues, which represents an increase of 481.8% Y/Y. In addition, the company's gross profit was $237.3 million, while its vehicle margin was 21.2% against -7.4% a year ago. During the period, NIO has also improved its bottom-line performance, as its net loss was only $68.8 million, and despite the chip shortages and the Chinese New Year its deliveries have also increased by 422.7% Y/Y and by 15.6% Q/Q to 20,060.</p>\n<p>One of the best things about NIO is that it already has a dominant position in the Chinese EV industry and it also has a solid balance sheet, as its cash reserves at the end of Q1stoodat $7.2 billion, while it had only $1.59 billion in long-term debt. As a result, it can easily reinvest its resources back into the business to drive growth and establish an even stronger foothold in its home market without worrying too much about the current losses.</p>\n<p>On top of that, while some might say that by trading at a price-to-salesratioof ~13x NIO is overvalued, the reality is that its momentum is not slowing down and there's every reason to believe that the growth story is far from over. Considering that even at the market cap of ~$70 billion NIO still trades below the Streetconsensusprice of $59.24 per share, it's safe to assume that the upside is still there, especially since the current forecasts suggest that the company will increase its revenues from $2.49 billion in FY20 to $8.81 billion in FY22.</p>\n<p><img src=\"https://static.tigerbbs.com/71905e5a90565b6a7e8864b3f6b0c226\" tg-width=\"883\" tg-height=\"382\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Seeking Alpha</i></p>\n<p>At this stage, the major competitor of NIO's flagship SUVES8is Tesla's Model X. However, there are several reasons to believe that the ES8 is a more attractive car in comparison to the Model X, and as a result, NIO has all the opportunities to outsell its competitor in China in the long run. First of all, the ES8 has more legroom and headroom than the Model X, it also has a luxurious interior, and it comes with three different battery packages that could last from 415 kilometers to 580 kilometers on a single charge.</p>\n<p>All of the ES8 SUVs include a proprietary operating system, have advanced navigation software, and most importantly cost ~$70,000 per vehicle in China, which is below the cost of Tesla's Model X, which comes at a price tag of ~$110,000 per vehicle in the region. We believe that this pricing advantage will undoubtedly help NIO to outsell Tesla in the SUV segment, especially since its cars now could bepurchasedat a discount thanks to the new Chinese subsidy program.</p>\n<p>Another uniqueness of NIO is its battery as a service business model, which allows its customers to swap their batteries in various swapping stations around China if they don't want to charge their cars or are in a hurry. After recently deploying the second version of its Power Swap stations, the swapping of batteries is now done in under three minutes, which is the same as refueling a traditional ICE car, and a single station now could perform up to 312 battery swaps in a single day. NIO now has a network of charging stations across all of China and if the solid-state batteries won't be available by the end of the decade at scale, then the idea of swapping batteries on the go will remain a viable business model in the long run.</p>\n<p>Going forward, NIO plans to accelerate its deliveries this month in order to meet its Q2 goal of delivering 21,000 to 22,000 vehicles, which represents a growth of 103% Y/Y to 113% Y/Y and plans to generate $1.24 to $1.29 billion in revenues during the period. Despite the semiconductor shortages, NIO already managed to increase its deliveries in April and May to 7,102 vehicles and 6,711 vehicles, respectively, which represents a growth of 125% Y/Y and 95.3% Y/Y, respectively. On top of that, NIO is also on track to deliver 90,000 to 100,000 vehicles this year.</p>\n<p>Considering this, there's every reason to believe that NIO will continue to be a dominant player in the Chinese EV market and a leader of the luxury EV segment in the region. While the company doesn't have an infrastructure outside China, we don't think that's a downside at all since China is the biggest EV market in the world that's constantly growing and NIO has better chances of creating shareholder value there than abroad. For that reason, we believe that NIO's growth story is far from over and it's likely that as long as its deliveries increase with every quarter, its stock will be rising in value in the long run.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO: Buy This Chinese EV Manufacturer While It's Still Cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO: Buy This Chinese EV Manufacturer While It's Still Cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434085-nio-buy-this-chinese-ev-manufacturer-while-its-still-cheap><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nNIO is a dominant EV manufacturer in the electric SUV segment in China.\nDespite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434085-nio-buy-this-chinese-ev-manufacturer-while-its-still-cheap\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4434085-nio-buy-this-chinese-ev-manufacturer-while-its-still-cheap","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1146386859","content_text":"Summary\n\nNIO is a dominant EV manufacturer in the electric SUV segment in China.\nDespite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla.\nAs the Chinese EV market will continue to aggressively expand in the upcoming years, we believe that NIO has all the chances to create additional shareholder value in the future.\n\nNIO(NYSE:NIO)is a dominant EV manufacturer in the electric SUV segment in China. It has been constantly increasing its deliveries every quarter, its revenues have been growing at a triple-digit rate in recent years, and despite competing in the luxurious SUV segment, its cars are more affordable in comparison to the cars of its peers such as Tesla(NASDAQ:TSLA). While NIO's stock has depreciated last month, there's every reason to believe that its growth story is far from over, as the Chinese EV market will continue to aggressively expand in the upcoming years and the penetration of electric vehicles on its roads is only going to increase. Considering this, the company has all the chances to create additional shareholder value in the long run.\nDominating the Chinese Market\nFounded in 2014, NIO is an electric vehicle manufacturer that's headquartered in Shanghai, China. The company mostly specializes in the development of luxurious electric SUVs and just likeXPeng(XPEV), it manufactures and sells its cars online and through its showrooms across China. In addition, NIO also offers various energy-related solutions such as home charging stations, mobile charging services, and others to its customers.\nIn recent years, the company has been aggressively growing, as the deliveries of its cars have been steadily increasing quarter after quarter, which led to the appreciation of its stock. However, due to the overall market selloff last month, NIO's stock along with stocks of other EV manufacturers such as XPeng, Tesla, and Li Auto (LI) evaporated most of its YTD gains and are currently underperforming the S&P 500 Index.\n\nChart: Seeking Alpha\nDespite this, there's every reason to believe that NIO's stock will recover, as the company's successful performance in Q1 shows that its growth story is far from over. InQ1alone NIO beat the Street expectations by $160 million and generated $1.22 billion in revenues, which represents an increase of 481.8% Y/Y. In addition, the company's gross profit was $237.3 million, while its vehicle margin was 21.2% against -7.4% a year ago. During the period, NIO has also improved its bottom-line performance, as its net loss was only $68.8 million, and despite the chip shortages and the Chinese New Year its deliveries have also increased by 422.7% Y/Y and by 15.6% Q/Q to 20,060.\nOne of the best things about NIO is that it already has a dominant position in the Chinese EV industry and it also has a solid balance sheet, as its cash reserves at the end of Q1stoodat $7.2 billion, while it had only $1.59 billion in long-term debt. As a result, it can easily reinvest its resources back into the business to drive growth and establish an even stronger foothold in its home market without worrying too much about the current losses.\nOn top of that, while some might say that by trading at a price-to-salesratioof ~13x NIO is overvalued, the reality is that its momentum is not slowing down and there's every reason to believe that the growth story is far from over. Considering that even at the market cap of ~$70 billion NIO still trades below the Streetconsensusprice of $59.24 per share, it's safe to assume that the upside is still there, especially since the current forecasts suggest that the company will increase its revenues from $2.49 billion in FY20 to $8.81 billion in FY22.\n\nSource: Seeking Alpha\nAt this stage, the major competitor of NIO's flagship SUVES8is Tesla's Model X. However, there are several reasons to believe that the ES8 is a more attractive car in comparison to the Model X, and as a result, NIO has all the opportunities to outsell its competitor in China in the long run. First of all, the ES8 has more legroom and headroom than the Model X, it also has a luxurious interior, and it comes with three different battery packages that could last from 415 kilometers to 580 kilometers on a single charge.\nAll of the ES8 SUVs include a proprietary operating system, have advanced navigation software, and most importantly cost ~$70,000 per vehicle in China, which is below the cost of Tesla's Model X, which comes at a price tag of ~$110,000 per vehicle in the region. We believe that this pricing advantage will undoubtedly help NIO to outsell Tesla in the SUV segment, especially since its cars now could bepurchasedat a discount thanks to the new Chinese subsidy program.\nAnother uniqueness of NIO is its battery as a service business model, which allows its customers to swap their batteries in various swapping stations around China if they don't want to charge their cars or are in a hurry. After recently deploying the second version of its Power Swap stations, the swapping of batteries is now done in under three minutes, which is the same as refueling a traditional ICE car, and a single station now could perform up to 312 battery swaps in a single day. NIO now has a network of charging stations across all of China and if the solid-state batteries won't be available by the end of the decade at scale, then the idea of swapping batteries on the go will remain a viable business model in the long run.\nGoing forward, NIO plans to accelerate its deliveries this month in order to meet its Q2 goal of delivering 21,000 to 22,000 vehicles, which represents a growth of 103% Y/Y to 113% Y/Y and plans to generate $1.24 to $1.29 billion in revenues during the period. Despite the semiconductor shortages, NIO already managed to increase its deliveries in April and May to 7,102 vehicles and 6,711 vehicles, respectively, which represents a growth of 125% Y/Y and 95.3% Y/Y, respectively. On top of that, NIO is also on track to deliver 90,000 to 100,000 vehicles this year.\nConsidering this, there's every reason to believe that NIO will continue to be a dominant player in the Chinese EV market and a leader of the luxury EV segment in the region. While the company doesn't have an infrastructure outside China, we don't think that's a downside at all since China is the biggest EV market in the world that's constantly growing and NIO has better chances of creating shareholder value there than abroad. For that reason, we believe that NIO's growth story is far from over and it's likely that as long as its deliveries increase with every quarter, its stock will be rising in value in the long run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114266217,"gmtCreate":1623075922339,"gmtModify":1634037214012,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"The next GameStop!","listText":"The next GameStop!","text":"The next GameStop!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114266217","repostId":"2141286115","repostType":4,"repost":{"id":"2141286115","kind":"highlight","pubTimestamp":1623052500,"share":"https://www.laohu8.com/m/news/2141286115?lang=&edition=full","pubTime":"2021-06-07 15:55","market":"us","language":"en","title":"3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will","url":"https://stock-news.laohu8.com/highlight/detail?id=2141286115","media":"Motley Fool","summary":"The long-term prospects look much brighter for these great companies.","content":"<p>There's a good reason why <b>AMC Entertainment</b> ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.</p><p>Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.</p><p><img src=\"https://static.tigerbbs.com/8615f62a24d693e4bc1bbaeadc93a39c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h2><a href=\"https://laohu8.com/S/FB\">Facebook</a></h2><p>Don't believe for <a href=\"https://laohu8.com/S/AONE\">one</a> second that lots of people have thrown in the towel on&nbsp;<b>Facebook</b> (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.</p><p>Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"</p><p>The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.</p><p>As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.</p><h2>Moderna</h2><p><b>Moderna</b> (NASDAQ:MRNA) stands as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.</p><p>As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.</p><p>Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.</p><p>But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.</p><h2>Square</h2><p>Like AMC,&nbsp;<b>Square</b> (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.</p><p>Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.</p><p>The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and <b>Bitcoin</b>.</p><p>Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SQ":"Block","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141286115","content_text":"There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.Image source: Getty Images.FacebookDon't believe for one second that lots of people have thrown in the towel on Facebook (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.ModernaModerna (NASDAQ:MRNA) stands as one of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.SquareLike AMC, Square (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and Bitcoin.Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114268935,"gmtCreate":1623075846227,"gmtModify":1634037214578,"author":{"id":"3581911525047676","authorId":"3581911525047676","name":"sachisachi","avatar":"https://static.tigerbbs.com/9513faaae6ba7a1559b75abbf8730a60","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581911525047676","idStr":"3581911525047676"},"themes":[],"htmlText":"[Doubt]&nbsp;","listText":"[Doubt]&nbsp;","text":"[Doubt]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114268935","repostId":"1126396501","repostType":4,"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}